Learn To Invest
Stocks Special Reports LICs Credit Funds ETFs Tools SMSFs
Video Archive Article Archive
News Stocks Special Reports Funds ETFs Features SMSFs Learn
About

Company News Summary

Paradigm Biopharmaceuticals Receives Key Regulatory Approvals For MPS VI Study

18 Jun 2021  |  09:35:00  |  Associate analysts  |  Increase  |  Decrease  |  

Original announcement: PARADIGM RECEIVES KEY REGULATORY APPROVALS FOR MPS VI STUDY

Paradigm Biopharmaceuticals announced it has received regulatory approval from the Brazilian National Health Surveillance Agency, ANVISA, and ethics approval from CONEP, the Brazilian national ethics committee, for its Phase 2 clinical trial evaluating PPS in patients with MPS VI. A successful trial outcome will support partnering discussions for a registrational study to support the use of PPS, in conjunction with enzyme replacement therapy (ERT), in this orphan disease population.

Please click here for full details

See more ASX300 News Announcements